Stephen J Ramey1,2, Benjamin J Rich2, Deukwoo Kwon3, Eric A Mellon2, Aaron Wolfson2, Lorraine Portelance2, Raphael Yechieli2. 1. Department of Radiation Oncology, Georgia Cancer Center, Augusta University, Augusta, Georgia, USA. 2. Department of Radiation Oncology, Sylvester Comprehensive Cancer Center/University of Miami Miller School of Medicine, Miami, USA. 3. Biostatistics and Bioinformatics Core, Sylvester Comprehensive Cancer Center/University of Miami Miller School of Medicine, Miami, USA.
Abstract
BACKGROUND: Prolonged time to treatment initiation (TTI) for patients with curable anal cancer may reduce tumor control. This study investigated demographic disparities in TTI for patients receiving definitive chemoradiation (CRT) for anal squamous cell carcinoma (A-SCC). METHODS: Adult patients with A-SCC diagnosed from 2004 to 2014 and treated with definitive CRT were identified in the National Cancer Database (NCDB). TTI was defined as days from diagnosis to start of CRT. A negative binomial regression model estimated predicted TTI (pTTI) values. Cox proportional hazards model evaluated the impact of TTI on overall survival (OS). RESULTS: Overall, 12,546 patients were included with 9% Non-Hispanic Black patients and 4% Hispanic patients. Multivariable analysis (MVA) showed that pTTI varied significantly by race/ethnicity with Non-Hispanic Black patients having a pTTI of 50 vs. 38 days for Non-Hispanic White patients [relative risk (RR), 1.21; 95% confidence interval (CI), 1.17-1.25]. For Hispanic patients, pTTI was 48 days, significantly longer than that of Non-Hispanic White patients (RR, 1.19; 95% CI, 1.14-1.24). Gender, insurance status, education level, urban category, distance to reporting facility, treatment facility type, intensity-modulated radiation therapy (IMRT)/proton use, T/N classification, and comorbidity status were all also associated with significant variation in TTI. TTI was not independently associated with changes in OS on MVA [hazard ratio (HR), 0.999; 95% CI, 0.997-1.002]. CONCLUSIONS: Non-Hispanic Black and Hispanic patients have longer delays in starting definitive CRT for A-SCC. While TTI was not associated with OS, future analyses should explore the impact of TTI on local control, metastases, and patient-reported outcomes.
BACKGROUND: Prolonged time to treatment initiation (TTI) for patients with curable anal cancer may reduce tumor control. This study investigated demographic disparities in TTI for patients receiving definitive chemoradiation (CRT) for anal squamous cell carcinoma (A-SCC). METHODS: Adult patients with A-SCC diagnosed from 2004 to 2014 and treated with definitive CRT were identified in the National Cancer Database (NCDB). TTI was defined as days from diagnosis to start of CRT. A negative binomial regression model estimated predicted TTI (pTTI) values. Cox proportional hazards model evaluated the impact of TTI on overall survival (OS). RESULTS: Overall, 12,546 patients were included with 9% Non-Hispanic Black patients and 4% Hispanic patients. Multivariable analysis (MVA) showed that pTTI varied significantly by race/ethnicity with Non-Hispanic Black patients having a pTTI of 50 vs. 38 days for Non-Hispanic White patients [relative risk (RR), 1.21; 95% confidence interval (CI), 1.17-1.25]. For Hispanic patients, pTTI was 48 days, significantly longer than that of Non-Hispanic White patients (RR, 1.19; 95% CI, 1.14-1.24). Gender, insurance status, education level, urban category, distance to reporting facility, treatment facility type, intensity-modulated radiation therapy (IMRT)/proton use, T/N classification, and comorbidity status were all also associated with significant variation in TTI. TTI was not independently associated with changes in OS on MVA [hazard ratio (HR), 0.999; 95% CI, 0.997-1.002]. CONCLUSIONS: Non-Hispanic Black and Hispanic patients have longer delays in starting definitive CRT for A-SCC. While TTI was not associated with OS, future analyses should explore the impact of TTI on local control, metastases, and patient-reported outcomes.
Entities:
Keywords:
Anus neoplasms; chemoradiotherapy; healthcare disparities; radiotherapy; treatment delay
Authors: Mechteld R M Visser; J Jan B van Lanschot; Jacobus van der Velden; Jaap J Kloek; Dirk J Gouma; Mirjam A G Sprangers Journal: J Surg Oncol Date: 2006-06-01 Impact factor: 3.454
Authors: Janet R Daling; Margaret M Madeleine; Lisa Godefroy Johnson; Stephen M Schwartz; Katherine A Shera; Michelle A Wurscher; Joseph J Carter; Peggy L Porter; Denise A Galloway; James K McDougall Journal: Cancer Date: 2004-07-15 Impact factor: 6.860
Authors: Jennifer E Devoe; Alia Baez; Heather Angier; Lisa Krois; Christine Edlund; Patricia A Carney Journal: Ann Fam Med Date: 2007 Nov-Dec Impact factor: 5.166
Authors: Ramin Roohipour; Sujata Patil; Karyn A Goodman; Bruce D Minsky; W Douglas Wong; José G Guillem; Philip B Paty; Martin R Weiser; Heather B Neuman; Jinru Shia; Deborah Schrag; Larissa K F Temple Journal: Dis Colon Rectum Date: 2008-01-08 Impact factor: 4.585
Authors: Suleyman Y Goksu; Muhammet Ozer; Syed M A Kazmi; Todd A Aguilera; Chul Ahn; David Hsiehchen; Aravind Sanjeevaiah; Mary C Maxwell; Muhammad S Beg; Nina N Sanford Journal: Am J Clin Oncol Date: 2020-11 Impact factor: 2.787